Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

about

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

Item

http://www.wikidata.org/entity/Q42656077

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@en

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@nl

type

Item

label

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@en

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@nl

prefLabel

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@en

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@nl

P1476

Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.

@en

P2093

Ana Graf

http://www.w3.org/2001/XMLSchema#string

Angelika Caputo

http://www.w3.org/2001/XMLSchema#string

Giovanni Marotta

http://www.w3.org/2001/XMLSchema#string

J Michael Ryan

http://www.w3.org/2001/XMLSchema#string

Judit Sovago

http://www.w3.org/2001/XMLSchema#string

Marie-Emmanuelle Riviere

http://www.w3.org/2001/XMLSchema#string

Martin Farlow

http://www.w3.org/2001/XMLSchema#string

R Paul Maguire

http://www.w3.org/2001/XMLSchema#string

P2860

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Aluminum salts in vaccines--US perspective

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

Active immunotherapy options for Alzheimer's disease.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

P304

10-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRCI.2016.12.003

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Philip Scheltens

Rik Vandenberghe

Raquel Sanchez-Valle

P577

2016-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29067316

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

immunotherapy

P932

5651373

http://www.w3.org/2001/XMLSchema#string